Want to see HK:8329 full AI Analyst Report?
8329 Stock Chart & Stats
HK$0.16
>-HK$0.01(-0.63%)
At close: 4:00 PM EST
HK$0.16
>-HK$0.01(-0.63%)
Day’s Range― - ―
52-Week RangeHK$0.09 - HK$0.18
Previous CloseN/A
Volume90.00K
Average Volume (3M)330.65K
Market Cap
HK$179.55M
Enterprise ValueHK$22.56M
Total Cash (Recent Filing)HK$209.45M
Total Debt (Recent Filing)HK$73.02M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.02%
Share Statistics
EPS (TTM)-0.02
Shares Outstanding426,000,000
10 Day Avg. Volume371,000
30 Day Avg. Volume330,653
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)0.25
P/FCF Ratio1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA debt-to-equity around 0.10–0.13 signals very low leverage, granting durable financial flexibility. This reduces interest burden, preserves borrowing capacity during stress, and allows the company to fund operations or strategic moves without forcing asset sales or excessive cost cutting.
Strong 2025 Free Cash FlowStrong FCF in 2025 despite a net loss indicates effective cash conversion and working-capital management. Durable cash generation enables funding of capex, R&D, dividends or debt reduction, providing resilience and optionality even while accounting earnings are pressured.
Positive Operating EarningsPositive operating earnings mean core operations remain profitable before non-operating items. That underlying operating profitability provides a structural base for recovery if non-recurring charges or financing costs abate, supporting medium-term operational stability.
Bears Say
Declining RevenueTop-line decline (revenue down ~4.7% in 2025; Fundamentals.RevenueGrowth -6.69%) indicates weakening demand or market-share erosion. Sustained revenue contraction undermines operating leverage, limits reinvestment capacity, and makes margin recovery and growth initiatives harder to fund.
Margin Compression And Net LossMaterial margin compression and a return to net losses reduce retained earnings and financial resilience. Lower margins shrink the buffer against rising input or SG&A costs, constrain reinvestment, and increase vulnerability to future demand or pricing shocks over the medium term.
Volatile Cash Flow HistoryHistorical swings in cash generation reduce confidence that the 2025 FCF run-rate is durable. Cash-flow volatility complicates multi-year planning for capex, dividends and R&D, raising execution risk even though the latest year showed a strong cash position.
8329 FAQ
What was Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price range in the past 12 months?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H lowest stock price was HK$0.09 and its highest was HK$0.18 in the past 12 months.
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap is HK$179.55M.
When is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date is Aug 07, 2026 which is in 2 days.
How were Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pay dividends?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pays a Notavailable dividend of HK$0.164 which represents an annual dividend yield of 5.02%. See more information on Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H dividends here
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H have?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H has 426,000,000 shares outstanding.
What happened to Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:8329
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
84.21%
12-Months-Change
Fundamentals
Return on Equity
5.02%
Trailing 12-Months
Asset Growth
-20.91%
Trailing 12-Months
Company Description
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
null
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) Earnings & Revenues
Technical Analysis
HUTCHMED (China)
―
Essex Bio-Technology
―
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
―
CanSino Biologics, Inc. Class H
―
Ab&B Bio-Tech CO., LTD. JS Class H
―